| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 240.5 | 191.5 | 158.6 |
| Other income | 7.6 | 7.7 | 11.9 |
| Total income | 248.1 | 199.1 | 170.5 |
| Profit before exceptional items & tax | 44.0 | 32.8 | 10.3 |
| Exceptional items | -0.6 | -0.2 | 0.0 |
| Profit before tax | 43.4 | 32.6 | 10.3 |
| Net profit | 34.2 | 24.7 | 8.0 |
| Operating margin | 17.5% | 16.4% | 6.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +327.50% |
|---|---|
| Net profit, quarter on quarter | +38.50% |
| Revenue, year on year | +51.60% |
| Operating profit, year on year | +2375.00% |
| Operating profit, quarter on quarter | +45.00% |
NSE results filing, NSE: INDSWFTLAB. Figures extracted from the filing.
Ind-Swift Laboratories Ltd: key numbers
- Share price
- ₹378.40
- Market cap
- ₹3,291 Cr
- Revenue (annual)
- ₹649.1 Cr
- Net profit (annual)
- ₹43.12 Cr
- P/E (TTM)
- 57.4×Sector 46.1×
- Promoter holding
- 42.93%+0.00% QoQ
- FII holding
- 10.78%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ind-Swift Laboratories Ltd
All →Ind-Swift Laboratories Board Meeting Date
Ind-Swift Laboratories Ltd. scheduled a board meeting for October 29, 2026, to consider and approve the standalone and consolidated financial results for the quarter and half-year.
Ind-Swift Laboratories Convertible Warrants
Essix Biosciences Limited acquired 14,00,000 equity shares of Ind-Swift Laboratories Limited following the conversion of fully convertible warrants. The company disclosed this under SEBI regulations.
Ind-Swift Laboratories Capital Structure Change
Ind-Swift Laboratories allotted 14,00,000 equity shares upon conversion of warrants at Rs. 196 each. The allotment follows a previously approved preferential issue.
- Value
- ₹27.44 Cr
Ind-Swift Laboratories Capital Structure Change
Ind-Swift Laboratories allotted 14 lakh equity shares upon converting warrants for Essix Biosciences Limited, receiving ₹20.58 Crore. This increases the company's paid-up equity share capital.
- Value
- ₹20.58 Cr
Ind-Swift Laboratories Annual General Meeting
Ind-Swift Laboratories Limited held its 31st Annual General Meeting on September 30, 2026. Members approved audited financial statements and director appointments.
Ind-Swift Laboratories Other Announcement
KMP Pardeep Verma sold 6,140 equity shares of Ind-Swift Laboratories Ltd via market sale, reducing his holding by 0.01%.
- Value
- ₹0.25 Cr